MedPath
HSA Approval

XSP-BENA EXPECTORANT

SIN03335P

XSP-BENA EXPECTORANT

XSP-BENA EXPECTORANT

June 16, 1989

APEX PHARMA MARKETING PTE. LTD.

APEX PHARMA MARKETING PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantAPEX PHARMA MARKETING PTE. LTD.
Licence HolderAPEX PHARMA MARKETING PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Pharmacy Only
HSA Singapore Classification

Formulation Information

SUSPENSION

ORAL

Medical Information

R05CA10

combinations

Manufacturer Information

APEX PHARMA MARKETING PTE. LTD.

XEPA-SOUL PATTINSON (MALAYSIA) SDN BHD

Active Ingredients

AMMONIUM CHLORIDE

135 mg/5 ml

Ammonium chloride

DIPHENHYDRAMINE HCl

14 mg/5 ml

Diphenhydramine

SODIUM CITRATE

57.5 mg/5 ml

Sodium citrate

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

XSP-BENA EXPECTORANT - HSA Approval | MedPath